Abstract
The treatment of non-small cell lung cancer (NSCLC) has become increasingly biomarker-driven over the last decade, with a growing number of targeted therapies available for patients with specific genomic alterations. A fast-track screening of multiple molecular biomarkers is therefore required for first-line treatment selection in NSCLC, although challenging considering both turnaround time and sample quality. In an effort to improve the molecular diagnostic workup at our institution, we implemented a two-step reflex test (RT) at the time of pathological diagnosis of non-squamous NSCLC for EGFR, KRAS, BRAF, ERBB2, ALK, ROS1, PDL-1, RET, MET, and NTRK testing.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
